Japan health panel approves Merck’s oral COVID-19 treatment

The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.

U.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.
U.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.

A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck & Co Inc, part of Prime Minister Fumio Kishida’s plan to roll out new treatments by year-end as concerns rise about the Omicron variant.

The panel’s decision sets the stage for shipments of 200,000 doses across the country from this weekend, based on preparations announced earlier by Kishida.
“I’m convinced the distribution of this drug is a major step forward for our nation’s COVID-19 handling,” health minister Shigeyuki Goto told reporters after the decision, adding that some medical institutions and pharmacies will start receiving the pill as soon as next Monday.

Japan is betting heavily on oral treatments to keep serious infections and deaths at bay should a feared sixth wave of the pandemic emerge. The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir.

In addition, Kishida announced last week a deal to procure 2 million doses of a separate antiviral pill https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-covid-19-pill-near-90-effective-final-analysis-2021-12-14 developed by Pfizer Inc. And Japan’s Shionogi & Co is expected to soon file for approval of its own treatment https://www.reuters.com/article/healthcoronavirus-japan-shionogi/japans-shionogi-to-make-1-mln-doses-of-new-covid-19-treatment-by-early-2022-idUSL4N2QV1GW, supplying another 1 million doses by early next year.

U.S. regulators on Thursday authorized the Merck pill for certain high-risk adult patients.

Countries rushed to buy Merck’s molnupiravir after very promising initial results, but subsequent company data in late November indicated the drug was markedly less effective than previously thought. France cancelled its order on Wednesday.

Asked about the debate over its efficacy, Goto said on Friday the Japanese panel evaluated the use of molnupiravir based mainly on the earlier test result, while adding the updated result “does not negate this drug’s effectiveness”.

Japan this week confirmed the first known cases of Omicron infections that could not be traced back to overseas travellers. Community transmissions of the variant have now been found in the western cities of Osaka and Kyoto, and a suspected case was announced in Tokyo on Friday.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express Telegram Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.